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SELECTION OF THE MONTH 
Big Title: Gene therapy for Wilson’s disease: A distinct possibility 
Small titles,  
Cirrhosis: Multi-parametric MRI: A novel prognostic tool 
Phase 3b TURQUOISE-III trial 
Sequestrating miRNA-122 by chimeric HBV integration transcripts 
 
LIVER REGENERATION 
Gsα drives liver regeneration, biliary cell-driven hepatocyte regeneration, role 
of the gut-liver axis, PP2A terminates liver regeneration 
The stimulatory G protein α subunit (Gsα) participates in diverse cell processes and 
activates the cyclic AMP (cAMP)-dependent pathway by stimulating the production of 
cAMP. The role of Gsα in liver regeneration is poorly understood. Liu et al. addressed 
this question by using hepatocyte-specific Gsα gene knockout mouse. They now 
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show that the growth factor signaling pathway which promotes hepatocyte 
proliferation depends on Gsα signaling. 
During liver regeneration, liver cells are derived from pre-existing hepatocytes. If 
hepatocyte proliferation is compromised, biliary epithelial cells (BECs) can become the 
source of new hepatocytes but the mechanisms of how this is regulated is unknown. 
The paper by Ko et al. points to the important role of bromodomain and 
extraterminal (BET) proteins in driving biliary cell-driven hepatocyte 
regeneration providing novel investigational and therapeutic targets. 
Whether gut microbiota contributes to liver regeneration is unknown. Results by Liu et 
al. reveal that intestinal microbiota is involved in gene expression in regenerating 
livers. They also found that gene expression in these livers may be modulated by 
certain gut microbiome-derived bile acids. 
Little is known on inhibitors and stop signals that regulate liver regeneration. Lai et al. 
investigated the role of Ppp2cb (protein phosphatase 2 (formerly 2A), catalytic subunit, 
beta isoform, encoding PP2Ac) by performing 70% partial hepatectomy in hepatocyte-
specific Ppp2cb-deleted and wild-type mice. They found that PP2Ac through the 
Akt/Gsk3β/cyclin D1 pathway, plays a crucial role in the termination of liver 
regeneration.  
 
HEPATOCELLULAR CARCINOMA (HCC) 
Role of fatty synthase synthase in Akt-mediated hepatocarcinogenesis 
Aberrant lipogenesis may play a role in HCC. This is why Li et al. investigated the 
oncogenic potential of fatty acid synthase (encoded by Fasn) in the mouse liver. They 
show that fatty acid synthase overexpression is not oncogenic per se but is 
necessary for Akt-mediated cell survival oncogenesis. They found that fatty acid 
synthase activates Akt via the stimulation of the mammalian target of rapamycin 
complex 2 (known as mTORC2). The target for fatty acid synthase seems to be the 
rapamycin-insensitive companion of mTOR (known as RICTOR). Finally they show 
results suggesting that pharmacological blockade of fatty acid synthase is a 
promising approach for human HCC characterized by the activation of pro-
survival AKT. 
 
NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) 
Methionine and SAMe and steatosis, GLP-1 analogues in NASH, central obesity 
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and non-cirrhotic portal-vein thrombosis 
Autophagy plays a critical role in lipid catabolism (lipophagy), and defects in autophagy 
have been related to liver steatosis development. Since methionine and its metabolite 
S-adenosylmethionine (SAMe) are well known inactivators of autophagy, Zubiete-
Franco et al. aimed to examine whether high levels of both metabolites could block 
autophagy-mediated lipid catabolism. By performing elegant human and experimental 
studies, the authors demonstrate that elevated levels of methionine and SAMe can 
inhibit autophagic catabolism of lipids contributing to liver steatosis in mice and 
humans. 
GLP-1 (Glucagon-like peptide-1) analogues are useful for patients with type 2 
diabetes, but no prospective experimental data exists in NASH. Armstrong et al. 
determined the effect of a long-acting GLP-1 analogue, liraglutide, on organ-specific 
insulin sensitivity, hepatic lipid handling and adipose dysfunction in biopsy-proven 
NASH. They randomized 14 patients with NASH to receive either liraglutide or placebo 
for 12-weeks. Liraglutide reduced metabolic dysfunction, insulin resistance and 
lipotoxicity in the key metabolic organs in the pathogenesis of NASH. This study 
strongly suggests that liraglutide may offer the potential for a disease modifying 
intervention in NASH. 
Almost half of patients with non-cirrhotic portal vein thrombosis (PVT) do not have a 
clear predisposing factor, so they are considered idiopathic. Bureau et al. studied a 
series of patients with PVT and found that patients with idiopathic thrombosis have 
more frequently metabolic syndrome and central obesity than patients with a 
known predisposing factor. These results confirm previous studies showing that patient 
with fatty liver diseases and obesity are predisposed to develop PVT. Overall, these 
studies suggest that obesity and the resulting metabolic syndrome have prothrombotic 
effects and predispose to PVT. 
 
GENETIC METABOLIC DISEASES. 
Gene therapy for Wilson disease 
Current treatments for Wilson Disease (WD) are based on lifelong copper chelating 
drugs, which may cause side effects and do not restore normal copper metabolism. In 
this work, Murillo et al. assessed the efficacy of gene therapy by transducing the liver 
of the Atp7b-/- WD mouse model with an adenovirus encoding the human ATP7B 
cDNA. They observed a dose-dependent therapeutic effect of the gene therapy 
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approach manifested by the reduction of serum transaminases and urinary 
copper excretion, normalization of serum holoceruloplasmin, and restoration of 
physiological biliary copper excretion in response to copper overload. The liver of 
treated animals showed normalization of copper content and absence of histological 
alterations. These promising preclinical studies highlight that potential of gene therapy 
to treat patients with WD. 
 
HEPATITIS C 
Phase 3b TURQUOISE-III trial, effectiveness of polymerase inhibitor-free dual 
DAA combination 
Getting rid of ribavirin as part of all oral direct-acting antiviral (DAA) regimens 
represents a next important step in the global antiviral strategy implementing safe and 
easy-to-use treatment regimens aiming to eradicate hepatitis C virus (HCV) infection. 
While in patients with easy-to-treat characteristics adding ribavirin is not beneficial 
concerning antiviral response rates, its use is still recommended in more difficult-to-
treat patients with cirrhosis. In the single arm phase IIIb study (Turquoise-III), Feld et 
al. demonstrated, however, that a 12 week ribavirin-free 3D regimen consisting of 
ombitasvir, ritonavir-boostered paritaprevir and dasabuvir cured all 60 patients 
with HCV subtype 1b-induced compensated cirrhosis. Thus, the “ribavegan” 3D 
regimen can be given safely without sacrificing efficacy in compensated cirrhosis 
induced by HCV subtype 1b infection but should not be used in patients with subtype 
1a infection or a decompensated stage of the disease.  
Nucleosidic polymerase inhibitors (NUC) are an important backbone of interferon-free 
dual DAA regimens due to their high antiviral efficacy and high barrier to resistance, 
and are mainly used either in combination with an NS5A or protease inhibitor. 
However, whether a NUC-free dual regimen containing a first generation protease 
inhibitor plus NS5A inhibitor may represent an equally effective approach has not been 
widely studied in Caucasian patients. The phase II study by Zeuzem et al. is the first, 
evaluating the efficacy and safety of the combination of simeprevir (SMV) plus 
daclatasvir (DCV) when given for either 12 or 24 weeks with or without ribavirin in HCV 
subtype 1a or 1b responder as well as non-responder patients to previous interferon-
containing regimens. The overall response to the SMV plus DCV regimen was 
variable in the different subgroups (67-95%), and less robust as compared to 
NUC-containing dual, or non-NUC containing triple combinations. Altogether, the 
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results of this study together with more recent findings describing single virologic 
breakthroughs under SMV plus DAC therapy do not support further evaluation of this 
regimen. 
 
HEPATITIS B 
Cleaved c-FLIP mediates TNF-α-induced HBV suppression, sequestrating 
miRNA-122 by chimeric HBV integration transcripts – a new model for HBV-
induced hepatocarcinogenesis 
Reactivation of hepatitis B virus (HBV) infection have been observed in patients taking 
tumor necrosis factor alfa (TNF-α) blocking agents indicating a significant role of this 
cytokine in HBV replication control. TNF-α inhibits HBV replication in cell culture 
models, but the molecular mechanism and the downstream effector molecules 
involved its inhibitory action remain poorly understood. Park et al. were now able to 
demonstrate in an elegant study that p22-FLIP, a newly discovered anti-apoptotic 
cellular FLICE-inhibitory protein (c-FLIP) cleavage product, is generated by TNF-
α/NF-κB signaling pathway and strongly represses HBV replication at the 
transcriptional level through dysregulation of hepatocyte nuclear factors. The 
description of a novel function of p22-FLIP as a natural inhibitor of HBV infection, 
provides a novel mechanism by which TNF-α suppresses HBV non-cytolytically, and 
may open up new options for controlling HBV infection. 
HBV exerts its well established oncogenic potential by both direct as well as indirect 
mechanisms. However, HBV integration into the host genome represents most likely a 
key in the malignant transformation of the hepatocyte into liver cancer cells which 
occurs not randomly but rather within or near-repetitive, noncoding sequences, such 
as long interspersed nuclear elements (LINEs) and short interspersed nuclear 
elements (SINEs). Liang et al. describes for the first time that a HBV-human chimeric 
transcript, HBx-LINE1, possesses six binding sites for miR-122, and thus serves 
as a molecular sponge to sequester cellular miR-122, the most abundant liver-
specific miRNA which serves as a tumor suppressor and have been shown to be 
markedly decreased in HBV-infected liver cells and HBV-positive HCC tissues. The 
elegant study describes a novel mechanism by which HBV modulates hepatic cell 
function potentially involved in hepatocarcinogenic transformation.   
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IMAGING 
The Liver inflammation and Fibrosis score 
Rapid advances in technology have contributed to huge improvements in imaging. 
Pavlides et al. use simultaneous assessment of fibrosis, steatosis and iron 
using MRI scanning to define a novel prognostic score, the Liver inflammation 
and Fibrosis score (LIFs) and show its utility in predicting clinical outcomes in 
patients with chronic liver disease accurately. Further validation in large cohort will 
lead to an exciting new tool for prognostication.  
 
